All Posts

Critics say that the order will only shave a few months off of FDA approval, but it made Joe Rogan happy By Russell Payne Staff Reporter On Saturday, President Donald Trump signed an executive order expediting federal review of psychedelic drugs for treating mental illness, a class of drugs including LSD, psilocybin “magic” mushrooms and others that are highly illegal. Despite being banned, a wealth of research suggests they can treat intractable mental health problems, which

President Donald Trump has signed an executive order meant to fast-track government approval of certain psychedelics for therapeutic use.

The FDA’s existing frameworks, Colorado’s emerging program, and the case for pharmaceutical-grade standards in natural medicine. Federal signals around psychedelic medicine have been growing louder. Recent reporting suggests the current administration may push the FDA to accelerate review of psilocybin therapies already carrying Breakthrough Therapy designation, a development that brings a familiar question back into focus.

Homological scaffolds of brain functional networks

A dose of psilocybin, a dash of rabies point to treatment for depression

Psilocybin desynchronizes the human brain

Hallucinogenic drug found in 'magic mushrooms' eases depression, anxiety in people with life-threatening cancer

Psilocybin produces substantial and sustained decreases in depression

June 16, 2025 A new study conducted by Sunstone Therapies suggests that a single dose of psilocybin, combined with psychological support, can provide sustained relief from depression for some cancer patients. The study found that at the two-year follow-up: 53.6% of patients demonstrated a significant reduction in depression, and 50% had sustained depression reduction Additionally, 42.9% of patients experienced a sustained reduction in anxiety The research, led by Sunstone’s C

Could psilocybin help slow aging? A fascinating new study suggests it may extend the lifespan of human skin and lung cells by over 50% — with effects on telomere maintenance, oxidative stress, and DNA repair. While more human research is needed, the findings open the door to thinking differently about aging and wellness.

Recent clinical findings (General Hospital Psychiatry, 2026) indicate that symptom improvement within 24 hours after a psilocybin-assisted session is strongly predictive of sustained antidepressant benefit at 2, 4, 6, and 8 weeks in adults with treatment-resistant depression.

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

Decades after psychedelics were classified as Schedule I drugs with “no medical value,” science is forcing a reevaluation. From ketamine’s medical use to psilocybin and ibogaine advancing through clinical trials, researchers and clinicians are challenging stigma with data—driven by the urgent need to address PTSD, treatment-resistant depression, addiction, and the ongoing opioid crisis.

Colorado’s regulated psilocybin model is taking a different path than Oregon’s by prioritizing integration with existing healthcare. By allowing therapists to license their offices as micro-healing centers, Colorado enables talk therapy, psychiatry, and psilocybin services to coexist under one roof—creating a more accessible, trusted framework for psychedelic-assisted care.

Psylutions has appointed inflammation and microbiome expert Dr. Nichole R. Klatt to its Advisory Board, a major step in strengthening the science behind its psilocybin therapy offerings. Dr. Klatt brings over 20 years of research experience, including more than 100 peer-reviewed publications and leadership roles in precision medicine and surgical outcomes

Psychonaut POV Q&A with Rhonda DeSantis , Founder & Cultivator Henry Winslow-- December 14, 2025 You already run a successful construction company. Why get involved in the emerging psilocybin industry in Colorado at all? For me it was a life-changing experience. I had a very small dose of psilocybin that helped me through a critical time in my life, and from that one experience I had a dramatic reduction in trauma triggers. I did three more of those same small doses over the

Colorado Builds America’s First Psychedelic Care System

Psylutions Founder on Precision, Safety & Healing-Focused Psychedelic Care

Colorado Builds America’s First Psychedelic Care System

A New Chapter for Regulated Psilocybin Therapies